Table 2.

Clinical trials for tau immunotherapy: to facilitate the reading, the name of antibodies currently tested in clinical trials are given, but it should be kept in mind that their murine versions have been used in experimental models to assess their mode of action

Antibodies	Isotype	Epitope	Mode of action	Target population	Clinical trial phase	Clinical Trials.gov Identifier
BIIB076 (6C5)-Biogen	IgG1		Reduction in tau uptake and cell transfer [84, 134]	Healthy controls Mild AD	1/2	NCT03056729
BIIB092 (IPN002)-biogen	IgG4	N-terminus	Binding eTau: reduction in neuronal activation & Aß secretion [25]	AD PSP Tauopathies	1/2	NCT03352557 NCT02460094 NCT03068468 NCT03658135
ABBV 8E12 (HJ8.5)-abbvie	IgG4	N-terminus	Reduction in tau pathology [76, 98, 194]	PSP AD	1/2	NCT02985879 NCT03712787 NCT02880956
JNJ-63733657-johnson & johnson		pS217	Reduction in tau seeding [150]		1	NCT03375697
LY3303560B (MC1) lilly		N-terminus + conformation [aa7–9 and 312–34]	Reduction in tau pathology [35]	Healthy controls Mild/early AD	1/2	NCT02754830 NCT03019536 NCT03518073
RG7345 (anti-pS422)-Roche	N/A	pS422	Reduction in tau pathology [47]	Healthy controls Discontinued development	1	NCT02281786 (RO6926496)
RO7105705-Roche	IgG4	N-terminus	Reduction in tau pathology [8]	Healthy controls Mild AD	1/2	NCT02820896 NCT03289143 NCT03828747
UCB0107 (antibody D)-UCb Biopharma	IgG4	Mid- region close to MTBR	Reduction in uptake, cell transfer and seeding [2, 49]	Healthy controls	1	NCT03464227

The most advanced clinical trials (phases 1 and 2) include vaccination (AADvac1 and ACI-35, not shown) and passive immunotherapy (BIIB076, BIIB092 (Gosuranemab), ABBV-8E12 (Tilavonemab), JNJ-63733657, LY3303560 (Zagotenemab), RO7105705, UCB0107) and Lu-AF87908.